Journal of Neural Transmission

, Volume 116, Issue 2, pp 179–191

Risk of valvular heart disease associated with the use of dopamine agonists in Parkinson’s disease: a systematic review

  • Malcolm Steiger
  • W. Jost
  • F. Grandas
  • G. Van Camp
Parkinson's Disease and Allied Conditions - Review Article

DOI: 10.1007/s00702-008-0179-4

Cite this article as:
Steiger, M., Jost, W., Grandas, F. et al. J Neural Transm (2009) 116: 179. doi:10.1007/s00702-008-0179-4


A literature review was conducted to assess risk of cardiac valve regurgitation (CVR) associated with use of ergot-derived and non-ergot dopamine agonists (DAs) in patients with Parkinson’s disease (PD). Inclusion criteria: case-control/observational studies of >10 patients with PD treated with DAs, including a control group and assessment of incidence/risk of CVR. Of the 166 publications identified, 14 met all inclusion criteria and included 1,750 patients. In 11 of the studies, a significant increase in CVR frequency of any severity (at the aortic, mitral or tricuspid valve) in the ergot group vs. the non-ergot or control group was described. No study reported increased risk of CVR for non-ergot DAs, compared with controls. In the studies identified in the literature, the use of ergot-derived DAs (pergolide and cabergoline) in patients with PD was associated with increased risk of CVR. Increased risk of CVR was not associated with the use of non-ergot DAs.


Cardiac valve regurgitationParkinson’s diseaseDopamine agonistsValvular heart disease

Copyright information

© Springer-Verlag 2009

Authors and Affiliations

  • Malcolm Steiger
    • 1
  • W. Jost
    • 2
  • F. Grandas
    • 3
  • G. Van Camp
    • 4
  1. 1.The Walton Centre for Neurology and NeurosurgeryLiverpoolUK
  2. 2.Department of NeurologyGerman Diagnostic ClinicWiesbadenGermany
  3. 3.Department of NeurologyHospital Gregorio MarañónMadridSpain
  4. 4.Academic HospitalBrusselsBelgium